The insurer said it was targeting annual core earnings growth of more than 9% as part of its new three-year plan to 2027, after benefiting from a better-than-anticipated market.
Related Posts
Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD
Regeneron Pharmaceuticals and Sanofi have won FDA expanded approval of their blockbuster anti-inflammatory drug Dupixent in chronic obstructive pulmonary disease.
Auto & Transport Roundup: Market Talk
RENK Group, Delta Air Lines and more in the latest Market Talks covering the Auto and Transport sector.
Frasers Won’t Make Bid for Mulberry
The U.K. online fashion retailer has ended a near monthlong battle to take control of the British luxury brand.